Key result
Coronary sinus reducer reduces angina burden and improves quality of life in refractory angina.
Why the study?
Refractory angina remains a major global cardiovascular challenge with limited treatment options when further revascularization is not feasible, and the coronary sinus reducer is an emerging therapy with variable evidence and modest benefit in blinded studies.
Does coronary sinus reduction therapy relieve symptoms and improve quality of life in patients with refractory angina?
Does coronary sinus reduction therapy relieve symptoms and improve quality of life in patients with refractory angina?
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients. History is littered with examples of things we were convinced worked but really didn't.”
“A risk with the presentation of uncontrolled, unblinded, observational data is that the reported improvement in symptoms may be conflated by the reader with the true placebo-subtracted physical efficacy of the therapy.”
“There have been lots of unblinded single-arm studies [of CSR], but only three randomized controlled trials. We wanted to look at the different effect sizes between the unblinded and blinded studies to better understand the overall potential efficacy of the device.”
Coronary sinus reduction therapy is an emerging, safe option that may reduce angina burden and improve quality of life in appropriately selected patients with refractory angina.
Refractory angina is a chronic, debilitating condition characterized by persistent anginal symptoms despite optimal medical therapy and when further revascularization is not feasible. This condition is a major global cardiovascular healthcare challenge. The coronary sinus reducer represents an emerging therapeutic option intended to relieve symptoms by increasing coronary venous pressure and redistributing myocardial blood flow to ischemic subendocardial regions. Growing evidence has demonstrated improvements in angina class and quality of life, although results vary across studies and benefit magnitude is modest in blinded studies. This device appears to be safe and effective in reducing angina burden and improving quality of life in appropriately selected patients. Mechanistic understanding continues to evolve, and large ongoing randomized trials and meta-analyses aim to refine the indication, patient selection (including patients with microvascular angina), and long-term outcomes. Health-technology appraisals recognize potential clinical utility but call for more robust long-term data. This review provides an up-to-date description of the device, physiological rationale, clinical evidence, procedural technique, complications, and future directions. It also highlights knowledge gaps and discusses areas of on-going research.
No takes yet. Share an insight, caveat, or question.
Dash et al. (2026) conducted a review in Refractory angina. Coronary sinus reducer was evaluated. The coronary sinus reducer appears to be a safe and effective emerging therapeutic option to reduce angina burden and improve quality of life in appropriately selected patients with refractory angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: